Drug Search Results
More Filters [+]

EGP-437

Alternative Names: egp-437, egp437, egp 437
Latest Update: 2020-03-31
Latest Update Note: News Article

Product Description

The EyeGate II Delivery System and EGP-437 combination product, is being evaluated for the treatment of pain and inflammation in patients having undergone cataract surgery with implantation of a monofocal posterior chamber IOL (intraocular lens).

Mechanisms of Action: GR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Ocular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Kiora Pharmaceuticals
Company Location: WALTHAM MA 02452
Company CEO: Brian M. Strem
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EGP-437

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Iridocyclitis|Uveitis, Anterior

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EGP-437-006

P3

Completed

Uveitis, Anterior|Iridocyclitis

2018-04-20

73%

Recent News Events